AbbVie Inc News and Headlines -

GuruFocus Articles Total 330
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 17

Pfizer trades with a valuation well off of its 10-year average

Shares of Pfizer (PFE) have declined almost 7% since I last looked at the company in depth. Despite this weakness, I believe that the company has strong prospects for growth. The stock continues to offer a dividend yield that is superior to its long-term average while trading with a very low price-earnings multiple.

This article will examine why I think Pfizer remains a strong buy for investors looking for exposure to the health care sector.

Quarterly highlights

Pfizer reported second quarter earnings results on July 28. The company's revenue fell 11% year-over-year to $11.8 billion, but managed to

653 Views    Nathan Parsh    2020-09-18 16:13
Swiss giant adds third drug to its portfolio this year

Swiss food and beverage giant Nestle (OTCPK:NSRGY) is paying more than $2 billion for Aimmune Therapeutics, Inc. (AIMT) to bag the California-based company's drug Palforzia, a peanut allergy medication that was approved by the Food and Drug Administration earlier this year.

Nestle already owned more than 25% of Aimmune. The all-cash deal values the company at $2.6 billion. At $34.50 per share, the price amounts to a 174% premium on Aimmune's closing price as of Friday, as Nestlé said in the news release. The purchase is expected to close in the fourth quarter of 2020.

Adding Aimmune will

179 Views    Barry Cohen    2020-09-01 15:27
Other pharmas working on stem cells to repair degenerative brain damage

The last three categories of drugs being studied for Alzheimer's are metabolic approaches, stem cell and gene therapies and alternative medicines. The first four were reviewed previosly, with the most popular approach being aimed at the physical changes (amyloid/tau) in the brains of Alzheimer's patients.

Diabetes is a metabolic disease, so some scientists speculate that Alzheimer's is really the third type of diabetes, according to FierceBiotech. That's because some forms of Alzheimer's seem to be related to insulin resistance, the main problem in type 2 diabetes. Research has shown that people with this form of diabetes have a greater risk

97 Views    Barry Cohen    2020-08-28 20:11
Merger arbitrage specialist releases 2nd-quarter portfolio

John Paulson (Trades, Portfolio), head of investment firm Paulson & Co., disclosed his second-quarter portfolio earlier this month.

With the long-term goal of capital preservation, above-average returns and low correlation to the market, the guru's New York-based firm specializes in event-driven arbitrage strategies, including merger arbitrage, bankruptcy reorganizations and distressed credit.

Sticking to these criteria, the investor revealed he established four new positions during the quarter, exited seven stocks and added to or reduced a number of other holdings. Notable transactions included the addition of TD Ameritrade Holding Corp. (AMTD) to the portfolio, as well as significant

278 Views    Sydnee Gatewood    2020-08-25 16:30
Klarman student releases portfolio

David Abrams (Trades, Portfolio), founder of Abrams Capital Management, disclosed this week that he sold out of Suburban Propane Partners LP (SPH), boosted his position in Kinder Morgan Inc. (KMI) and eliminated over 90% of his stake in Pacific Drilling SA (PACD) during the second quarter.

Managing a portfolio of 22 stocks, the pupil of Baupost Group manager Seth Klarman (Trades, Portfolio) seeks companies in which the CEO has a significant stake or where the CEO's salary is primarily stock-based. Abrams employs a value approach to investing.



576 Views    James Li    2020-08-13 22:17
Firm reveals top trades of the 2nd quarter

Investment firm Tweedy Browne (Trades, Portfolio) disclosed its second-quarter portfolio earlier this week.

The New York-based firm, which has been operating for a century, is an investment partnership that is owned and operated by its four managing directors, William H. Browne, John D. Spears, Thomas H. Shrager and Robert Q. Wyckoff Jr. Deriving its investment approach from the work of Benjamin Graham, the firm oversees around $4.5 billion in assets through four unique mutual funds. Each of the portfolios is managed according to the same value principles with an emphasis on seeking undervalued stocks.

In the

212 Views    Sydnee Gatewood    2020-08-12 18:44
UnitedHealth on the list

According to the GuruFocus All-in-One Screener, a Premium feature, the stocks of the following guru-owned health care companies have outperformed the S&P 500 Index over the past 12 months through July 10.


UnitedHealth Group Inc. (UNH) has a market cap of $287.94 billion. It has outperformed the S&P 500 by 7.42% over the past year.

Shares are trading with a price-earnings ratio of 7.08. As of Friday, the share price was 61.74% above the 52-week low and 3.87% below the 52-week high.

The company has a GuruFocus profitability rating of 8 out of 10. The return on

70 Views    Tiziano Frateschi    2020-08-07 15:24
Their dividend yields beat that of the S&P 500

Dividend investors may be interested in the following stocks, as they are currently significantly outperforming the S&P 500 index in terms of higher dividend yields. The benchmark for the U.S. market grants an average yield of 1.78% as of Aug. 7.

Furthermore, Wall Street sell-side analysts have issued positive recommendation ratings for these stocks, suggesting that their share prices are expected to trade higher.

AbbVie Inc

The first company that makes the cut is AbbVie Inc (ABBV), a U.S. drug major based in North Chicago, Illinois.

Based on Thursday's closing price of $92.57 per share, AbbVie Inc grants a

124 Views    Alberto Abaterusso    2020-08-07 14:58
The company is confident Reyvow will be key competitor in market forecast to reach $13 billion by 2027

Eli Lilly and Co.’s (LLY) new migraine medication, Reyvow, is giving the pharma giant a bit of a headache.

Overall, the company's second-quarter sales fell below expectations. The new acute migraine medication Reyvow failed to make up the revenue shortfall caused by customers stockpiling medications when the pandemic began, thus causing ongoing sales to take a hit. Revenues fell 2.4% to $5.5 billion compared to the same period a year earlier.

A bright spot was that new medications made up more than half of sales in the quarter. FiercePharma reported that in the wake of that performance, Cantor

114 Views    Barry Cohen    2020-08-06 16:42
The stock trades with a single-digit multiple despite strong growth rates from products outside of Humira

The last time I looked at AbbVie Inc. (ABBV) was following my early February purchase of the stock. At that time, I felt that shares had at least 30% upside. AbbVie recently reported earnings results, and nothing in the report has changed my thesis on the stock. I still believe that shares can offer at least a 30% increase in share price.

Quarterly highlights

AbbVie reported second-quarter earnings results on July 31. The company’s revenue increased 26.3% to $10.4 billion, beating Wall Street analysts’ estimates by almost $290 million. Adjusted earnings per share improved 8 cents, or 3.5%, to

706 Views    Nathan Parsh    2020-08-02 19:31
During same 10-year period, Eisai and Abbott were worst performers in measure

Among the largest publicly traded pharmaceutical companies, Novo Nordisk (NVO) and Roche (RHHBY) had the highest returns on invested capital during the period from 2011 to 2019, according to a report from the Westhealth Policy Center. At the other end of the spectrum were Abbott Laboratories (ABT) and Easai Co. (TSE:4523).

In simplest terms, ROIC is a profitability ratio that indicates just how efficient a company is turning capital into profit. It measures the return that an investment generates for those who have provided capital (i.e., bondholders and stockholders).

ROIC can be important to investors because it is a key

106 Views    Barry Cohen    2020-07-28 20:35
Building protections for new cancer drug, just as it did with Humira

Chicago-area pharmaceutical giant AbbVie Inc. (ABBV) is following the same winning strategy with its new cancer treatment that it did with its drug Humira, which is forecast to reach record-shattering cumulative sales of $240 billion by 2024.

Its plan? Build an impenetrable wall around the new Imbruvica, which is used to treat B cell cancers, via creative—some would say manipulative—use of the patent system.

AbbVie has become known as the master builder of patent walls, according to an article in Endpoints. “Its work on Humira has been both legendary and extraordinarily controversial, encircling a cash cow that can

301 Views    Barry Cohen    2020-07-24 21:11
Some companies may turn to acquisitions to boost revenues

Previously, I listed the 15 members of Big Pharma that are expected to record the highest sales in 2026, as reported by EvaluatePharma. Now we’ll look at the products and strategies that will propel the top five companies’ revenue.

Roche Holding AG (RHHBY)

  • Estimated 2026 sales: $61.9 billion
  • 2019 sales: $48.2 billion
  • 2019 to 2026 CAGR: 3.62%

Although the Swiss company is expected to suffer a $10 billion shortfall when three of its top-selling cancer drugs lose exclusivity, replacements are expected to step into the breach. That was the case in the first quarter, when two

233 Views    Barry Cohen    2020-07-14 21:42
AstraZeneca and Bristol-Myers Squibb's revenues expected to grow the fastest

Thanks to the introduction of drugs in three major disease areas, Roche (RHHBY) is expected to retain its position as the number one member of Big Pharma in terms of sales, according to a report from Evaluate Pharma.

The Swiss company’s revenues are forecast to reach $62 billion in 2026, growing at a compound rate of more than 3.6% from 2019. Pfizer Inc. (PFE) is expected to capture the number two spot with sales of just over $56 billion. Others reaching the $50 billion plus level are Johnson & Johnson (JNJ), Novartis (NVS), AbbVie Inc.(ABBV) and Merck & Co. Inc.

228 Views    Barry Cohen    2020-07-13 21:33
We have publicly tracked our portfolio since 2015, which has beaten the S&P 500 in terms of total return over this period of time. Most importantly, dividend income continues to grow

The portfolio that my wife and I are building has been publicly tracked since 2015 on a different platform. As this is the first posting of our portfolio’s performance on GuruFocus, I would like to give some background information about us and our investment goals and strategies.

Investment goals and strategies

We have nicknamed our portfolio “The March to Freedom” because we believe that investing is a long game and that there are no short-term solutions to creating a portfolio that can be used to pay for retirement.

Our portfolio consists of our Roth Individual Retirement Accounts and a workplace

143 Views    Nathan Parsh    2020-07-07 18:42
Recently, these companies have been able to achieve yearly highs.

According to GuruFocus, the following stocks have reached their 52-week highs.

Lowe's reached the 52-week high of $135.76

Lowe's Companies Inc. (LOW) is the second-largest home improvement retailer in the world, operating about 1,970 stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair and remodeling. Lowe's targets retail do-it-yourself and do-it-for-me customers as well as commercial business clients.

The price of Lowe's Companies Inc. shares has reached $135.76, which is 1.8% off the 52-week high of $138.25. Lowe's Companies Inc. has a market

26 Views    yifan900    2020-07-07 14:40
GlaxoSmithKline's efficiency illustrates its ability to do more with less

In a June 11 article for GuruFocus, I looked at the R&D efforts underway at the top five spenders in the pharmaceutical industry last year. Now, let’s take a look at the work being done by those in positions five through 10.

6. Sanofi

R&D budget: €6.02 billion ($6.52 billion)

Change from 2018: +2.2%

Total 2019 revenue: €36.13 billion ($39.15 billion)

R&D budget as percentage of revenue: 16.7%

Sanofi (SNY), under the leadership of former Roche executive John Reed, is reorienting its R&D efforts to strengthen its position in oncology and other specialty care areas, according to FierceBiotech.


127 Views    Barry Cohen    2020-06-14 14:16
Nasdaq jumps to record high, Tiffany up on earnings report

US markets

U.S. stocks were mixed on Tuesday after rallying the past days, with energy, financials and industrials leading declines. The Dow Jones Industrial Average lost 0.80% to 27,353, the S&P 500 index fell 0.65% to 3,211 and the Nasdaq Composite Index was up 0.23% to 9,948.


• Newmont Corporation (NEM) +2.3%

• Abbvie Inc (ABBV) +1.6%

• Clorox Co (CLX) +1.5%

• Eli Lilly and Co (LLY) +1.3%

• ServiceNow Inc (NOW) +0.9%

• Johnson & Johnson (JNJ) +0.6%


• Coty Inc (COTY) -11%

• Concho Resources Inc (CXO) -9%

• Simon Property Group Inc (SPG)

82 Views    Omar Venerio    2020-06-09 16:57
The S&P 500 is expensive again, but there is still value to be found

It can be difficult for investors to find undervalued stock with the S&P 500 trading at a price-earnings multiple near 23. For income investors, finding stocks with generous yields is also becoming tricky.

In this article, we will look at five high-yielding stocks that trade at a lower valuation than the S&P 500.

AbbVie Inc.

AbbVie Inc. (ABBV) was spun off from Abbot Laboratories (ABT) in 2013. The company’s Humira was the best-selling drug in the world for quite some time. Humira has lost patent protection in the European Union already and will do the same in the U.S. in

1248 Views    Nathan Parsh    2020-06-07 14:22
Partnership with Arcus Biosciences follows acquisitions of Kite Pharmaceuticals and Forty Seven

It its latest foray into oncology, Gilead Sciences Inc. (GILD) chose to rent rather than own.

Instead of acquiring Arcus Biosciences Inc. (RCUS), as has long been rumored, Foster City, California-based Gilead struck a $2 billion partnership deal with the five-year-old biotech. Under the 10-year pact, the companies will develop and market therapies designed to treat cancers through the body’s immune system.

Though the agreement may be highly lucrative for Arcus down the line, investors had been looking for a quicker payday. They had bid the stock up nearly 280% since the beginning of the year, banking on a buyout.

159 Views    Barry Cohen    2020-05-29 21:47

Headlines Total 659
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2020-09-24 $ 86.21 (-1.07%)
2020-09-22 $ 88.6 (-0.55%)
2020-09-21 $ 89.09 (-1.13%)
2020-09-18 $ 90.11 (0.54%)
2020-09-17 $ 89.63 (-0.17%)
2020-09-16 $ 89.78 (-1.24%)
2020-09-15 $ 90.91 (0.46%)
2020-09-14 $ 90.49 (0.88%)
2020-09-12 $ 89.7 (0.06%)
2020-09-11 $ 89.7 (0.06%)
Is AbbVie Stock a Buy? -
2020-09-10 $ 89.65 (-2.16%)
2020-09-09 $ 91.63 (1.56%)
2020-09-08 $ 90.22 (-1.8%)
2020-09-07 $ 91.87 (%)
2020-09-04 $ 91.87 (%)
2020-09-02 $ 93.95 (1.85%)
2020-09-01 $ 92.24 (-3.69%)
2020-08-31 $ 95.77 (1.7%)
2020-08-28 $ 94.17 (-0.14%)
2020-08-27 $ 94.3 (-0.05%)
2020-08-26 $ 94.35 (0.31%)
2020-08-25 $ 94.06 (-0.48%)
2020-08-24 $ 94.51 (-0.37%)
2020-08-21 $ 94.86 (-0.36%)
2020-08-20 $ 95.2 (-0.94%)
2020-08-19 $ 96.1 (0.47%)
2020-08-18 $ 95.65 (-0.73%)
2020-08-17 $ 96.35 (1.35%)
2020-08-14 $ 95.07 (0.41%)
2020-08-13 $ 94.68 (-0.87%)
2020-08-12 $ 95.51 (3.06%)
2020-08-11 $ 92.67 (0.31%)
2020-08-10 $ 92.38 (-0.58%)
2020-08-07 $ 92.92 (0.38%)
2020-08-05 $ 93.25 (-1.1%)
2020-08-04 $ 94.29 (-1.72%)
2020-08-03 $ 95.94 (1.09%)
2020-07-31 $ 94.91 (-1.18%)
Total 659
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7